Grant Bishop

Tuesday, 10 November 2026 · Markets closed · Edition 20

The Index › Metabolic medicine › Whose sales may the drugs shrink?

Campbell Soup

CPB

Campbell Soup sells packaged soups, snacks and sauces. We follow it because its sales depend on eating habits that weight-loss drugs and health trends may change.

Checked against the company's own business description in its latest annual filing. · entry updated 2026-10-19
Ticker
CPB
Exchange
—
Price
—
Change
—
As of
—
Market cap
—
EV/EBIT
—
P/E NTM
—
FCF yield
—
Net debt/EBITDA
—
Next earnings
—

Last refreshed from 10-K filed (EDGAR)

Follow · Add to calendar · Daily window

The living report

Bears on our standing view that AI's economy-wide productivity lift does not arrive before 2028. It is proved wrong if productivity jumps much sooner than we expect, or adoption stops spreading.

last revised 19 Oct 2026 · next scheduled disclosure 8 Dec 2026 · results for the quarter ending Oct 2026
The full report

Members: queues this company for a report on a coming night.

The market record

Free during the preview. Each figure shows only where two independent data providers, Massive and Yahoo, agree on it to the cent; a figure they do not agree on is left out. Dated, not live. It describes; it does not recommend.

Last close$23.13
close of 6 Nov 2026 · Massive and Yahoo agree
The day's range$22.56 – $23.27
6 Nov 2026 · both providers agree
52-week range$18.60 – $32.04
intraday low 7 Oct 2026 · intraday high 21 Nov 2025 · 251 sessions to 6 Nov 2026 · both providers agree
Market value$6.9 billion
the 6 Nov 2026 close × 298,234,693 shares outstanding on the 10-K cover, as of 16 Sep 2026
$

Enter any price. The page shows the multiple on the forward estimate on file and where that price sits in the 52-week range. It computes; it does not recommend.

Filings

Newest first, from EDGAR. Where a piece read a filing, one line of what it said.

5 Oct 20268-K · period ending 1 Oct 2026
24 Sep 202610-K · period ending 2 Aug 2026
17 Sep 20268-K · period ending 16 Sep 2026
3 Sep 20268-K · period ending 3 Sep 2026
17 Jun 20268-K · period ending 17 Jun 2026
8 Jun 202610-Q · period ending 3 May 2026
8 Jun 20268-K · period ending 8 Jun 2026
11 Mar 202610-Q · period ending 1 Feb 2026
11 Mar 20268-K · period ending 11 Mar 2026
15 Dec 20258-K · period ending 11 Dec 2025
9 Dec 20258-K · period ending 8 Dec 2025
9 Dec 20258-K · period ending 9 Dec 2025
9 Dec 202510-Q · period ending 2 Nov 2025
9 Dec 20258-K · period ending 9 Dec 2025
19 Nov 20258-K · period ending 18 Nov 2025
7 Oct 20258-K · period ending 2 Oct 2025
18 Sep 202510-K · period ending 3 Aug 2025
5 Sep 20258-K · period ending 2 Sep 2025
3 Sep 20258-K · period ending 3 Sep 2025
5 Aug 20258-K · period ending 5 Aug 2025
18 Jul 20258-K · period ending 17 Jul 2025
2 Jun 202510-Q · period ending 27 Apr 2025
2 Jun 20258-K · period ending 2 Jun 2025
5 Mar 202510-Q · period ending 26 Jan 2025
5 Mar 20258-K · period ending 5 Mar 2025
24 Feb 20258-K · period ending 24 Feb 2025
4 Dec 202410-Q · period ending 27 Oct 2024
3 Dec 20248-K · period ending 1 Dec 2024
20 Nov 20248-K · period ending 19 Nov 2024
12 Nov 20248-K · period ending 12 Nov 2024

Where it sits in the frame

Reports next

8 Dec 2026 · expected, per Nasdaq · results, quarter to Oct 2026

What it bears on

Latest disclosed

10-K · filed 2026-09-24 · period ending 2026-08-02

Read the filing

Machine-readable

/index/CPB.json

What it has disclosed

Newest first. Every figure traces to a filing; "Show sources" shows which.

—No figure from this company appears in a committed piece yet.

Mentioned in

Every piece that names this company, newest first: what it said, and the standing view it bore on. Written when the piece is committed; never edited, never removed.

—No piece names this company yet.

Same question

Other companies under Whose sales may the drugs shrink?

This entry

19 Oct 2026Entry rewritten in plain words: what the company sells, and why we follow it.
12 Oct 2026Verified against the 10-K filed 2026-09-24 at launch.

Prices on this page are dated market records, shown free during the preview, each confirmed by two independent data providers. None is a recommendation.

Follow Campbell Soup. The weekly piece, and a note when a filing moves it.

Record

Written according to the Grant Bishop standard — machine-researched, machine-checked, human-judged; then read and committed by the publisher. Every number traces to a filing or a dated market record; every claim carries a date and what would prove it wrong.

Verification
multi-source verified, machine-drafted, human-gated
As of
2026-09-24
Position disclosure
The publisher holds index-level U.S. equity exposure and no direct position in any single name discussed.
Not advice
General commentary for a general audience. Not advice for your situation.
Sources (12)